



Cyxone appoints Urban Ottosson as new CFO

Cyxone (publ), a biotech company in autoimmune diseases, has recruited Urban Ottosson as new Chief Financial Officer (CFO) as of June 15th 2023, replacing Ola Skanung.

Urban has a M.Sc. in Business and Economics degree from Lund university and has attained an Executive Diploma from KTH Executive School in Stockholm. He has held several CFO positions in a range of publicly listed companies and has a strong background in M&A, business strategy, Investor Relations, and financial management. Urban will succeed Ola Skanung, who has been the company's CFO since 2022 as well as previous years between 2015-2021.

"I am grateful to be offered the CFO role in Cyxone. I look forward to contributing to driving the projects forward and thus helping people with autoimmune diseases", says Urban Ottosson.

"We are very happy to welcome Urban Ottosson to our team. Urban brings a considerable knowledge with his many years in M&A, fund raising, business strategy and financial management. He will be a fantastic support for the company and the journey we have ahead. At the same time, I would like to thank Ola for his great commitment to Cyxone these past years and appreciate that he will still be there in the background as an advisor to the company", says Carl-Magnus Högerkorp, CEO at Cyxone.

Contact

Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com